home / stock / rnlx / rnlx news

RNLX News and Press, Renalytix AI plc From 07/03/23

Stock Information
Company Name: Renalytix AI plc
Stock Symbol: RNLX
Market: NASDAQ
Website: renalytix.com
Menu
RNLX RNLX Quote RNLX Short RNLX News RNLX Articles RNLX Message Board
Get RNLX Alerts

News, Short Squeeze, Breakout and More Instantly...
RNLX - Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, annou...
RNLX - Analyze Penny Stocks Charts Like a Pro With These Tips 

2023-07-01 11:16:00 ET 3 Tips for Analyzing Penny Stocks Charts Like a Pro Navigating the world of penny stocks—those enticing equities trading at less than $5 per share—can be a rewarding yet complex endeavor. The high volatility that characterizes these assets offers uni...

RNLX - AAOI, RXT and GRCL among mid-day movers

2023-06-30 12:31:22 ET Gainers: Cyteir Therapeutics ( CYT ) +39% . Renalytix ( RNLX ) +39% . Rackspace Technology ( RXT ) +29% . Friedman Industries ( FRD ) +23% . Gracell Biotechnologies ( GRCL ) +23% . CytomX Therapeutics (...

RNLX - Renalytix PLC (NASDAQ: RNLX) Near the Top of Equities by Percentage Gain on 6/30

Renalytix PLC (NASDAQ: RNLX) is one of today's top gainers. The company's shares are currently up 36.95% on the day to $2.78. Renalytix PLC develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that em...
RNLX - CymaBay, Cyteir top healthcare gainers; Unicycive, Apyx among losers

2023-06-30 10:06:37 ET Gainers: CymaBay Therapeutics ( CBAY ) +36% . Cyteir Therapeutics ( CYT ) +34% . Renalytix ( RNLX ) +32% . CytomX Therapeutics ( CTMX ) +14% . Alvotech ( ALVO ) +13% . Losers: Unicycive Therapeutics ...

RNLX - FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease

Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United States LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renal...

RNLX - KidneyIntelX(TM) Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that three scientific abstracts have been accepted at the upcoming American Diabetes Association 83 rd Scientific Sessions (June 23-26, 2023) in San Diego, California and anot...
RNLX - Renalytix plc (RNLX) Q3 2023 Earnings Call Transcript

2023-06-09 12:42:08 ET Renalytix plc (RNLX) Q3 2023 Results Conference Call June 09, 2023 08:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO Tom McLain - President James Sterling - CFO Conference Call Participants ...

RNLX - Sientra, ContraFect top healthcare gainers; Elevation, Longboard among losers

2023-06-09 10:07:38 ET Gainers: Sientra ( SIEN ) +65% . ContraFect ( CFRX ) +47% . Societal CDMO ( SCTL ) +20% . Akili ( AKLI ) +14% . Erasca ( ERAS ) +12% . Losers: Elevation Oncology ( ELEV ) -41% . Longboar...

RNLX - Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, toda...
Previous 10 Next 10